Form 4: STAAR SURGICAL Grants RSUs to Interim Co-CEO Foust

STAAR Surgical Co. awarded 20,787 restricted stock units to Interim Co-CEO and President & COO Warren Foust in connection with his appointment.

Summary

• Warren Foust, Interim Co-CEO and President & COO of STAAR Surgical Co., was granted 20,787 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.
• The RSUs were awarded on February 2, 2026, coinciding with his appointment as Interim Co-Chief Executive Officer.
• These RSUs are scheduled to vest 100% on August 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and the formalization of an interim leadership role, which provides clarity on management structure.

Positives

• The grant of RSUs aligns management's incentives with shareholder interests, encouraging long-term performance.
• The award is tied to the appointment of Warren Foust as Interim Co-CEO, indicating a structured compensation plan for key leadership.

Future Outlook

The 20,787 RSUs granted to Warren Foust are scheduled to vest 100% on August 1, 2026, indicating a future equity payout tied to his continued service.

Management Comments

• This Form 4 reflects the RSUs granted to Mr. Foust in connection with his appointment as Interim Co-Chief Executive Officer on February 2, 2026.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units, are a standard component of executive compensation packages across the medical device and ophthalmology sectors. This practice aims to align executive incentives with long-term company performance and shareholder value creation, a common strategy for retaining and motivating key leadership.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a common practice among publicly traded companies, including peers in the medical device industry such as Alcon (ALC) or Bausch + Lomb (BLCO), to incentivize long-term performance and retention.
• The vesting schedule of 100% on a single date (August 1, 2026) for an interim role's grant is typical for short-term or transitional executive appointments, differing from multi-year vesting schedules often seen for permanent executive roles.

Management Changes

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with shareholder interests, potentially leading to improved long-term performance. It also signals stability in interim leadership.
• Employees: The formalization of an interim Co-CEO role provides clarity in leadership structure.

Next Steps

• The 20,787 RSUs granted to Warren Foust are expected to vest on August 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) tied to an interim leadership appointment. While it provides transparency regarding insider holdings and management incentives, it does not present new information that would fundamentally alter the company's financial outlook or strategic direction. Therefore, a "hold" recommendation is appropriate as this filing alone does not warrant a change in investment thesis.

Keywords

STAAR Surgical, STAA, Warren Foust, Restricted Stock Units, RSU, Executive Compensation, Interim Co-CEO, Corporate Governance, Insider Transaction